The social implementation project for hemoCD, the world’s first CO antidote and the core technology of our center, has been selected for HVC Kyoto (Healthcare Venture Conference Kyoto). Prof. Hiroaki Kitagishi of Doshisha University will present at HVC KYOTO 2026 Demo Day, held at Kyoto Research Park on July 13–14, 2026.
HVC Kyoto is one of Japan’s largest acceleration programs supporting promising healthcare and deep-tech startups from Japan and abroad. Through this selection, our center will receive expert support in business strategy, fundraising, and global expansion.
hemoCD is the world’s first chemical antidote designed to directly capture CO and remove it from the body. It is an innovative technology intended to enable rapid medical intervention at fire, disaster, and accident sites. This selection will further accelerate our clinical development and commercialization activities.